• $3.0M
    Market Cap
  • -99.20%
    1-Year Change
  • Medical Devices
    Industry

Key Performance

More
  • Earnings Score: N/A
  • Momentum Score: 54
  • True Yield: N/A
  • Financial Health Score: N/A
TradeSmith Loading

Latest Research & News

INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic "Family Beginnings"

INVO Fertility (NASDAQ: IVF) has successfully closed its acquisition of Family Beginnings, an Indiana-based fertility clinic, for $760,000 in cash and preferred stock. The clinic generated approximately $1 million in revenue and $0.2 million in net income for the 9 months ended September 30, 2025. The acquisition expands INVO's geographic footprint and aligns with its strategy to increase access to high-quality fertility care while maintaining the clinic's existing medical leadership under Dr. James Donahue.

02/19/2026, 8:30 AMBenzinga

Why INVO Fertility (IVF) Stock Is Trending Overnight

INVO Fertility (NASDAQ:IVF) shares fell 14.78% to $2.02 in after-hours trading on Tuesday, despite closing the regular session up 191.73% at $2.37. The company signed a definitive agreement to acquire Family Beginnings fertility clinic for $750,000 and reported Q3 2025 revenue growth of 23% year-over-year to $1.76 million. However, the company posted a net loss of $2.6 million, and the stock has declined 98.25% over the past 12 months, trading near its 52-week low.

01/20/2026, 9:48 PMBenzinga

INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic “Family Beginnings”

INVO Fertility plans to acquire Family Beginnings, a respected fertility clinic in Indiana, as part of its strategic expansion across the Midwest. The acquisition aims to enhance clinical capabilities and broaden access to innovative fertility care.

11/28/2025, 1:05 PMGlobeNewswire

INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic "Family Beginnings"

INVO Fertility plans to acquire Family Beginnings, a respected Indiana fertility clinic, marking its second acquisition in expanding a nationwide network of fertility centers. The strategic move aims to broaden treatment options and improve patient care across the Midwest.

11/28/2025, 1:05 PMBenzinga

INVO Fertility Announces a 1:8 Reverse Stock Split Effective Pre-Market Opening on November 28, 2025

INVO Fertility will implement a 1-for-8 reverse stock split effective November 28, 2025, reducing outstanding shares to approximately 1,891,151 and adjusting authorized shares to 6,250,000.

11/25/2025, 9:00 AMGlobeNewswire

INVO Fertility Adds Platelet-Rich Plasma Therapy Capabilities at Wisconsin Fertility Institute

INVO Fertility has introduced Platelet-Rich Plasma (PRP) therapy at its Wisconsin Fertility Institute, offering a new treatment option for patients facing fertility challenges by using the body's own growth factors to potentially improve implantation rates and ovarian rejuvenation.

06/30/2025, 9:00 AMGlobeNewswire

Peers

Statistics

More
Day Range
$1.60
$1.89
$1.70
1-Year Range
$0.25
$3.46
$1.70
Latest Close$1.70
Change
+$0.18 (+10.59%)
Volume441,524
Market Cap$3.0M
Shares Outstanding1.6M
P/E (TTM)-0.004
Diluted EPS (TTM)-$435.94
Enterprise Value$3.8M

Information as of 06/03/2026

Company Profile

$3.0M
Market Cap
-$9.7M
Net Income
Sector: Healthcare
Industry: Medical Devices
5582 Broadcast Court, Sarasota, FL, United States, 34240
978 878 9505

INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. It also operates fertility clinics, including INVO Centers. In addition, the company develops NY-303, a GPC3 x NKp46 bifunctional antibody that is in Phase i/ii a monotherapy trial for the treatment of hepatocellular carcinoma; and NY-500, an AI-optimized bifunctional antibody. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.

Key Executives

  • Steven Shum
  • Andrea Goren
  • Terah Krigsvold

Current Ownership Distribution

  • Other958,273 (68.83%)
  • Insiders228,322 (16.40%)
  • Institutions192,053 (13.79%)
  • Mutual Funds13,572 (0.97%)